Actively Recruiting
Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-11-06
200
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of 5 in 10,000 pregnancies. This rare condition is associated with placental inflammatory lesions leading to severe and recurrent obstetrical complications: intrauterine growth retardation (IUGR), fetal death in utero and miscarriage. The pathophysiological mechanisms of CHI are poorly understood, while the empirical treatments prescribed to prevent recurrence are cumbersome and of poor efficacy. Recent findings suggest that an alloimmune response may play a role. In a recent work, the investigators have demonstrated the role of maternal alloantibodies directed against fetal HLA antigens in two patients followed for recurrent IUGR associated with CHI. Their work suggests that a humoral alloimmune response directed against fetal HLA antigens mimics an allograft rejection process. The investigators propose to extend the preliminary results obtained in these patients to provide new insights into the pathophysiological mechanisms of CHI, and eventually to predict the risks of fetal loss.
CONDITIONS
Official Title
Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Mother and father 18 years old or older
- Mothers in the CHI group with a history of normal pregnancy or IUGR, fetal death in utero, miscarriage, or abortion followed by at least one obstetrical complication such as IUGR, fetal death, or miscarriage
- Diagnosis of chronic histiocytic intervillositis confirmed by placental examination with CD68+ marking for mothers in the CHI group
- Mothers with antiphospholipid syndrome and history of miscarriage
- Mothers in the normal pregnancy group with a third consecutive normal pregnancy at term (36 weeks or more) with a healthy child
- Consent from mother and father to participate in the study and for use of existing samples from previous pregnancies or miscarriages
- Father must be the father of the last pregnancy and child(ren) participating in the study
You will not qualify if you...
- For mothers in the normal pregnancy group: suspected or confirmed intra-amniotic infection
- For all mothers: history of blood transfusion
- For all mothers: history of allogeneic organ transplantation
- For mother and father: persons under legal protection such as guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Antoine Béclère Hospital
Clamart, France
Actively Recruiting
Research Team
A
Alexandra LETOURNEAU, Doctor
CONTACT
A
Alexandra BENACHI, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here